NVAX - Novavax, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Gaithersburg,
United States
Type: Equity
NVAX price evolution
NVAX
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $578.93 | $661.5 | $516.27 | $635.28 |
| Short term investments | ||||
| Net receivables | $297.24 | $123.66 | $394.89 | $112.85 |
| Inventory | $41.7 | $69.59 | $23.49 | $34.19 |
| Total current assets | $1143.89 | $1006.76 | $1127.55 | $971.03 |
| Long term investments | ||||
| Property, plant & equipment | $490.99 | $491.72 | $395.69 | $411.34 |
| Goodwill & intangible assets | $127.45 | $123.78 | $128.37 | $129.83 |
| Total noncurrent assets | $653.6 | $650.39 | $557.49 | $571.67 |
| Total investments | ||||
| Total assets | $1797.49 | $1657.16 | $1685.05 | $1542.7 |
| Current liabilities | ||||
| Accounts payable | $132.61 | $101.91 | $87.25 | $124.8 |
| Deferred revenue | $863.52 | $801.03 | $907.41 | $689.83 |
| Short long term debt | $5.14 | $1.33 | $0.95 | $1.21 |
| Total current liabilities | $1635.14 | $1468.59 | $1596.26 | $1918.86 |
| Long term debt | $223.94 | $220.78 | $197.99 | $197.85 |
| Total noncurrent liabilities | $879.28 | $866.92 | $843.31 | $519.42 |
| Total debt | $229.08 | $222.11 | $198.94 | $199.06 |
| Total liabilities | $2514.42 | $2335.51 | $2439.57 | $2438.28 |
| Shareholders' equity | ||||
| Retained earnings | -$4820.95 | -$4642.56 | -$4511.79 | -$4569.79 |
| Other shareholder equity | $2.72 | -$11.86 | -$8.18 | -$3.17 |
| Total shareholder equity | -$716.93 | -$678.35 | -$754.52 | -$895.58 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $578.93 | $1347.19 | $1526.61 | $648.74 |
| Short term investments | $157.65 | |||
| Net receivables | $297.24 | $82.38 | $454.99 | $262.01 |
| Inventory | $41.7 | $36.68 | ||
| Total current assets | $1143.89 | $1703.39 | $2155.12 | $1248.2 |
| Long term investments | ||||
| Property, plant & equipment | $490.99 | $400.49 | $228.7 | $179.95 |
| Goodwill & intangible assets | $127.45 | $126.33 | $136.25 | $141.1 |
| Total noncurrent assets | $653.6 | $555.29 | $421.63 | $334.28 |
| Total investments | $157.65 | |||
| Total assets | $1797.49 | $2258.68 | $2576.75 | $1582.48 |
| Current liabilities | ||||
| Accounts payable | $132.61 | $216.52 | $127.05 | $54.33 |
| Deferred revenue | $863.52 | $549.55 | $1595.47 | $273.23 |
| Short long term debt | $5.14 | $352.08 | $130.53 | $105.86 |
| Total current liabilities | $1635.14 | $2459.94 | $2390.32 | $579.67 |
| Long term debt | $223.94 | $197.7 | $323.46 | $362.12 |
| Total noncurrent liabilities | $879.28 | $432.81 | $538.11 | $375.6 |
| Total debt | $229.08 | $549.78 | $453.99 | $467.98 |
| Total liabilities | $2514.42 | $2892.76 | $2928.43 | $955.27 |
| Shareholders' equity | ||||
| Retained earnings | -$4820.95 | -$4275.89 | -$3617.95 | -$1874.2 |
| Other shareholder equity | $2.72 | -$6.38 | -$1.35 | $7.02 |
| Total shareholder equity | -$716.93 | -$634.08 | -$351.67 | $627.21 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $291.34 | $186.99 | $424.43 | $80.95 |
| Cost of revenue | $154.98 | $98.93 | $55.78 | $34.09 |
| Gross Profit | $136.37 | $88.06 | $368.65 | $46.87 |
| Operating activities | ||||
| Research & development | $164.7 | $106.23 | $219.47 | $247.1 |
| Selling, general & administrative | $155.24 | $107.46 | $93.72 | $112.53 |
| Total operating expenses | $319.93 | $213.69 | $313.19 | $359.63 |
| Operating income | -$183.57 | -$125.63 | $55.46 | -$312.77 |
| Income from continuing operations | ||||
| EBIT | -$172.58 | -$128.61 | $60.99 | -$288.41 |
| Income tax expense | $1.69 | -$0.7 | -$0.14 | $1.18 |
| Interest expense | $4.12 | $2.86 | $3.12 | $4.32 |
| Net income | ||||
| Net income | -$178.39 | -$130.78 | $58.01 | -$293.9 |
| Income (for common shares) | -$178.39 | -$130.78 | $58.01 | -$293.9 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $983.71 | $1981.87 | $1146.29 | $475.6 |
| Cost of revenue | $343.77 | $902.64 | ||
| Gross Profit | $639.94 | $1079.23 | $1146.29 | $475.6 |
| Operating activities | ||||
| Research & development | $737.5 | $1235.28 | $2534.51 | $747.03 |
| Selling, general & administrative | $468.95 | $488.69 | $298.36 | $145.29 |
| Total operating expenses | $1206.45 | $1723.97 | $2832.87 | $892.32 |
| Operating income | -$566.51 | -$644.74 | -$1686.58 | -$416.72 |
| Income from continuing operations | ||||
| EBIT | -$528.62 | -$633.77 | -$1693.41 | -$403.11 |
| Income tax expense | $2.03 | $4.29 | $29.21 | |
| Interest expense | $14.42 | $19.88 | $21.13 | $15.14 |
| Net income | ||||
| Net income | -$545.06 | -$657.94 | -$1743.75 | -$418.26 |
| Income (for common shares) | -$545.06 | -$657.94 | -$1743.75 | -$418.26 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$178.39 | -$130.78 | $58.01 | -$293.9 |
| Operating activities | ||||
| Depreciation | $10.79 | $11.32 | $10.07 | $9.04 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $15.66 | $20.76 | $20.29 | $28.65 |
| Total cash flows from operations | -$176.78 | -$39.66 | -$171.94 | -$325.59 |
| Investing activities | ||||
| Capital expenditures | -$9.08 | -$18.39 | -$7.78 | -$23.56 |
| Investments | ||||
| Total cash flows from investing | -$9.08 | -$18.39 | -$7.78 | -$23.56 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $102.71 | $195.36 | $61.79 | $0.54 |
| Net borrowings | -$2.32 | $1.76 | -$0.45 | -$351.33 |
| Total cash flows from financing | $100.39 | $197.12 | $61.34 | -$354.38 |
| Effect of exchange rate | $2.92 | $9.35 | -$0.62 | -$8.37 |
| Change in cash and equivalents | -$82.55 | $148.42 | -$119 | -$711.9 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$545.06 | -$657.94 | -$1743.75 | -$418.26 |
| Operating activities | ||||
| Depreciation | $41.23 | $29.05 | $157.09 | $250.75 |
| Business acquisitions & disposals | -$165.52 | |||
| Stock-based compensation | $85.36 | $130.3 | $183.63 | $128.03 |
| Total cash flows from operations | -$713.97 | -$415.94 | $322.95 | -$42.54 |
| Investing activities | ||||
| Capital expenditures | -$58.81 | -$92.98 | -$57.49 | -$54.62 |
| Investments | $157.64 | -$157.64 | ||
| Total cash flows from investing | -$58.81 | -$92.98 | $100.15 | -$377.78 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $360.4 | $248.59 | $589.62 | $920.09 |
| Net borrowings | -$352.35 | $81.66 | -$127.91 | -$96.06 |
| Total cash flows from financing | $4.47 | $324.99 | $461.71 | $984.76 |
| Effect of exchange rate | $3.27 | $4.52 | -$5.29 | $2.12 |
| Change in cash and equivalents | -$765.03 | -$179.41 | $879.52 | $566.56 |
News
|
12 Most Shorted Stocks in 2024
Insider Monkey via Yahoo Finance
19 Apr 2024
|
|
Novavax, Inc. (NASDAQ:NVAX) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance
29 Feb 2024
|
|
Novavax (NVAX) Q4 Earnings & Sales Miss Estimates, Stock Tanks
Zacks via Yahoo Finance
29 Feb 2024
|
|
Novavax: Q4 Earnings Snapshot
Washington Post
28 Feb 2024
|
|
Why Is Novavax Stock Trading Lower Today? - Novavax (NASDAQ:NVAX)
Benzinga
28 Feb 2024
|
|
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday’s Mid-Day...
Benzinga
28 Feb 2024
|
|
Stocks Poised for Muted Open
Barrons.com
25 Feb 2024
|
|
Fed's favorite inflation gauge looms next week — plus, what we want from 2 portfolio earnings...
CNBC
24 Feb 2024
|
|
Novavax settles COVID-19 vaccine dispute with Gavi Alliance By Investing.com
Investing.com
22 Feb 2024
|
|
Novavax settles dispute with international vaccine group Gavi
Reuters
22 Feb 2024
|
Fundamentals
| Market cap | $584.53M |
|---|---|
| Enterprise value | $234.68M |
| Shares outstanding | 139.51M |
| Revenue | $983.71M |
|---|---|
| EBITDA | -$487.39M |
| EBIT | -$528.62M |
| Net Income | -$545.06M |
| Revenue Q/Q | -18.48% |
| Revenue Y/Y | -50.36% |
| P/E ratio | -1.07 |
|---|---|
| EV/Sales | 0.24 |
| EV/EBITDA | -0.48 |
| EV/EBIT | -0.44 |
| P/S ratio | 0.59 |
| P/B ratio | -0.81 |
| Book/Share | -5.16 |
| Cash/Share | 4.15 |
| EPS | -$3.91 |
|---|---|
| ROA | -32.63% |
| ROE | 71.59% |
| Debt/Equity | -3.51 |
|---|---|
| Net debt/EBITDA | -3.97 |
| Current ratio | 0.70 |
| Quick ratio | 0.67 |